Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
N A DawsonC E Myers

Abstract

To assess the efficacy and toxicity of suramin, hydrocortisone, leuprolide, and flutamide in previously untreated metastatic prostate cancer. Patients with stage D2 and poor-prognosis stage D1 prostate cancer were given suramin on a pharmacokinetically derived dosing schedule to maintain suramin concentrations between 175 and 300 micrograms/mL. Additionally, all patients received flutamide 250 mg orally three times daily, initiated on day 1 and continued until disease progression; depot leuprolide 7.5 mg intramuscularly begun on day 5 and repeated every 4 weeks indefinitely; and replacement doses of hydrocortisone. Fifty patients were entered onto the study: 48 with stage D2 and two with stage D1 disease. The median age was 59 years (range, 42 to 79) and 31 patients had a Karnofsky performance status (KPS) of 100%. Forty-five patients had bone metastases and 25 had measurable soft tissue disease. Forty-one (82%) had severe disease. The overall response rate in 49 assessable patients was three complete responses (CRs) and 30 partial responses (PRs) for an overall response rate of 67%. Eighteen patients have died. The median survival time has not been reached, with a median potential follow-up duration of 44 months. Grade 3 to 4 ...Continue Reading

Citations

May 2, 2000·Anti-cancer Drugs·A Firsching-HauckB Allolio
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HussainE D Crawford
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E J SmallM Eisenberger
Dec 1, 2001·Expert Opinion on Biological Therapy·T G Zogakis, S K Libutti
Apr 18, 2001·Current Opinion in Oncology·B I Rini, E J Small
Jul 5, 2005·Expert Opinion on Investigational Drugs·H T Zhang, A L Harris
Dec 18, 2019·Antimicrobial Agents and Chemotherapy·Natalie WiedemarPascal Mäser
May 10, 2000·Clinical Pharmacokinetics·A RousseauG Lachâtre
Feb 8, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·David von der AheWolfgang Boehmerle
Jan 12, 2008·Molecular Cancer Therapeutics·Tristan M SissungAlex Sparreboom
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Akinobu HamadaWilliam D Figg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.